GRAIL's Galleri Multi-Cancer Early Detection Test Gains FDA Advisory Committee Support

In a landmark decision that could potentially revolutionize cancer screening practices, GRAIL, Inc., a pioneer in healthcare innovation, announced that its Galleri® multi-cancer early detection test (MCED) received a favorable recommendation from the U.S. FDA's Medical Devices Advisory Committee. This vote marks a critical milestone in the journey towards more effective cancer detection, particularly for those aged 50 and older who are at higher risk.

On September 23, 2026, the Committee convened to evaluate the safety, effectiveness, and overall benefit-risk profile of Galleri. In a series of votes, the committee members decisively expressed their support, with seven votes in favor, two against, and one abstention regarding the benefits of the test outweighing its risks. The unanimous decision on its safety was a significant confidence booster, while the split vote on effectiveness indicates an ongoing discourse among experts about its practical applications in clinical settings.

Dr. Josh Ofman, CEO of GRAIL, articulated the company’s mission to enhance the national cancer screening program through the introduction of Galleri, stating that the test aims to detect multiple cancers safely and cost-effectively, allowing for treatment when it remains most viable. This positive vote from the Committee serves as a robust endorsement of Galleri's clinical evidence, highlighting the company's commitment to maintaining a high standard in multi-cancer early detection.

How the Galleri Test Works

Galleri utilizes next-generation sequencing technology to identify unique cancer methylation patterns, providing the opportunity for the early detection of various cancer types, even those for which no standard screening currently exists. Designed to be used alongside existing guidelines for cancer screening, Galleri can enhance overall cancer detection efficacy by identifying cancer signals well before symptoms appear. When a potential cancer signal is detected, Galleri is capable of pinpointing the origin of these signals with remarkable accuracy, thus guiding healthcare professionals in further diagnostic evaluations.

The Importance of Advisory Committee Feedback

The FDA employs advisory committees like this one to gather independent expert opinions, which, while not binding, significantly inform the agency's final regulatory decisions. The Committee’s endorsement underscores the importance of advancing cancer screening methodologies and reflects a growing consensus that the early detection of cancers can significantly improve patient outcomes, especially in populations with limited options for proactive screening.

This discussion has been bolstered by the voices of over 200 stakeholders, including healthcare professionals, advocates, and patients who participated during the open comment period. Their collective input reflects a real-world urgency to expand cancer screening options that could save lives.

Clinical Trials and Evidence of Effectiveness

GRAIL has backed the Galleri test with extensive clinical studies, including the notable PATHFINDER 2 trial in North America and the NHS-Galleri trial in England. These studies demonstrated that Galleri has detected between four and seven times more cancers compared to standard practices, with a significant proportion of these detections emerging in earlier, more treatable stages of the disease.

Moreover, the test has maintained a low false-positive rate, reinforcing its promise for widespread clinical adoption. The FDA previously designated Galleri as a Breakthrough Device in 2018, indicating its potential significance in transforming cancer care paradigms.

Next Steps for FDA Approval

Following this committee vote, the FDA is expected to make its final decision on the PMA (Premarket Approval) application for Galleri soon. GRAIL emphasizes its commitment to working closely with the FDA throughout this review process, which could ultimately lead to broader access to Galleri for patients seeking early cancer detection.

Conclusion

GRAIL's Galleri test stands at the forefront of innovation in cancer detection, promising to augment existing methodologies and enhance overall patient outcomes through early diagnosis. As we await the FDA's final verdict, this high-profile committee recommendation serves as a hopeful sign for the future of cancer screening and the potential lives that could be saved through early detection strategies. Healthcare systems worldwide may soon benefit from this groundbreaking test, marking a significant advancement in the fight against cancer.

For more information about the Galleri test and GRAIL's mission, visit GRAIL's official website.